Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
Date:11/1/2007

erating expenses was non-cash share-based expense of $1.4 million and $2.0 million for the three months ended September 30, 2007 and 2006, respectively.

Net income was $12.3 million for the third quarter of 2007, compared to a net loss of $6.3 million for the third quarter of 2006. The positive nature of our operating results for the third quarter of 2007 was solely attributable to the termination of the ANA975 development program and the resulting recognition of deferred revenue from payments previously received from Novartis. Basic and diluted net income per common share was $0.43 in the third quarter of 2007, compared to net loss per common share of $0.22 for the same period in 2006. Non-cash share-based expense resulted in a $0.05 and $0.07 decrease (increase) in basic and diluted net income (loss) per share for the three months ended September 30, 2007 and 2006, respectively.

Revenues for the nine months ended September 30, 2007 were $23.9 million compared to $4.3 million for the same period in the prior year. Revenues for the nine months ended September 30, 2007 were primarily attributable to the recognition of the remainder of the $20 million up-front payment and the $10 million IND milestone payment, each of which were received from Novartis in 2005. For the nine months ended September 30, 2007, Anadys reported a net loss of $1.4 million compared to a net loss of $19.1 million for the same period last year. The reduction in Anadys' cumulative operating losses for the nine months ended September 30, 2007 compared to the same period in 2006 was almost entirely attributable to the termination of the ANA975 development program and the resulting recognition of deferred revenue from payments previously received from Novartis. Basic and diluted net loss per common share was $0.05 for the nine months ended September 30, 2007, compared to $0.67 for the same period in 2006.

As of September 30, 2007, the Company's cash, cash equivalents and securities
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Sept. 15, 2014 The chemistry, taste, and health ... a new article published by the nonprofit American Botanical Council ... climate change and its effects on the phytochemical compounds in ... study conducted by Dr. Ahmed in the Yunnan ... and has implications for the future of medicinal botanicals. Dr. ...
(Date:9/15/2014)...  The second annual International Plasma Awareness Week ... initiative of the Plasma Protein Therapeutics Association ... designed to: , Raise global awareness about ... plasma donors in saving and improving lives , ... diseases Member companies are planning a ...
(Date:9/13/2014)... 2014 Boehringer Laboratories Inc., with a ... to announce the successful broadcast of a live surgery ... Claros, MD, FACS, FAMBS, and Maher El Chaar, MD, ... System. , This sleeve gastrectomy surgery was performed ... than four hundred surgeons from around the world during ...
(Date:9/12/2014)... Mountain View, CA (PRWEB) September 12, 2014 ... its fundraising campaign on Indiegogo. , The film, ... Stephen Hawking, Buzz Aldrin, Shimon Peres, Ashton Kutcher, Will.i.Am, ... changing the world and there’s only one university in ... it to help change the lives of a billion ...
Breaking Biology Technology:Tea Taste and Quality Affected by Climate Change 2Tea Taste and Quality Affected by Climate Change 3Tea Taste and Quality Affected by Climate Change 4International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 3Boehringer Laboratories, Inc. Announces Live Surgery Using Innovative System to Calibrate Sleeve Gastrectomy 2Documentary Film that Follows Singularity University Students as They Change the World Launches its IndieGoGo Fundraising Campaign 2
... Dec. 20 Northwest,Biotherapeutics, Inc. (OTC Bulletin ... ("NWBT") announced today that Lonza Group AG ... NWBT,s DCVax(R)-Brain,product and other NWBT DCVax(R) products ... DCVax(R) cancer vaccine products infringed,certain gene expression ...
... teens and adults, HIGHLANDS RANCH, Colo., Dec. 19 ... its treatment services to,include a detox program. The new ... adults, and the hospital has added several new physicians ... abuse and,mental illness)., Teen suicide rates nationally are ...
... PALO ALTO, Calif., Dec. 19 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... V. Barron, MD, FACC to its Board of Directors. ... Medical Officer at Genentech,where he leads the Development organization, ... Dr. Barron joined Genentech in 1996 as a clinical ...
Cached Biology Technology:Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics 2Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics 3Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics 4Highlands Behavioral Health Hospital Unveils New Substance Abuse Detox Program 2Alexza Elects Dr. Hal V. Barron to Its Board of Directors 2Alexza Elects Dr. Hal V. Barron to Its Board of Directors 3
(Date:9/15/2014)... an unprecedented evolution experiment scientists from GEOMAR Helmholtz ... Institute of Sea Fisheries have demonstrated for the ... algae of the world,s oceans, Emiliania huxleyi ... rising water temperatures. In their study, the researchers ... evolutionary adaptations to these two aspects of climate ...
(Date:9/15/2014)... Ebola virus outbreak in West Africa, which has claimed ... a deeper understanding of the molecular biology of the ... vaccines or antiviral drugs to treat or prevent Ebola ... Virginia (UVA), USA under the leadership of Dr ... structural biologist has obtained the crystal structure of ...
(Date:9/15/2014)... September 15, 2014 Schizophrenia is generally considered to ... many risk factors, both genetic and environmental, with other ... The normal path for brain development is determined by ... and a wide range of environmental factors. , However, ... populations are required in order to map the disturbances ...
Breaking Biology News(10 mins):Small algae with great potential 2Small algae with great potential 3Protein secrets of Ebola virus 2Brain Development in Schizophrenia Strays from the Normal Path 2
... AUSTIN, Texas , April 17, 2013 Vermillion, ... company focused on gynecologic cancers and women,s health, announced the ... with the U.S. Army Medical Research and Materiel Command ... titled, "Cost Reduction Using OVA1 in a Treatment Algorithm ...
... Recent developments in postharvest disease control will be highlighted at ... sponsored by the University of California, Riverside Extension ... run from 8 a.m. to 5 p.m. Tuesday, April 23, and ... Santa Barbara . This year,s conference will include a large ...
... Committee for the Asian hornet, the Vespa velutina ... Community (region), the Charter Provincial Councils, the Beekeeping sector ... aimed at controlling the Vespa velutina populations ... an invasive species from France that preys on bees ...
Cached Biology News:U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 2U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 3U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 4Conference to highlight latest in postharvest pest control 2
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
... Mouse monoclonal [F30 P7 D7 ... for all tested applications). ... conjugated to Ovalbumin, corresponding to amino ... Entrez Gene ID: ...
DAP12 Market Segment: Protein Kinases...
G-protein coupled purinergic receptor P2Y8...
Biology Products: